Back to results
US 2019/0167728 A1Published application
In Vivo and Ex Vivo Expansion of Hematopoietic Stem Cells With a Targeted Combination of Clinically Tested, FDA Approved Drugs
AssigneeThe Trustees of the University of Pennsylvania
InventorsPeter S. Klein, Jian Huang
Life of this patent
Estimating the term…
Abstract
The present invention provides a therapeutic approach to maintain and expand HSCs in vivo using currently available medications that target GSK-3 and mTOR. The present invention also provides a system and method for the ex vivo culturing of HSCs, where an mTOR inhibitor is combined with a GSK-3 inhibitor within the culturing conditions.
Claims8
A culturing medium for expanding and maintaining a hematopoietic stem cell (HSC), comprising at least one glycogen synthase kinase-3 (GSK-3) inhibitor and at least one mammalian target of rapamycin (mTOR) inhibitor.
Dependencies are inferred from the claim text.